Neoadjuvant Letrozole and Palbociclib in Patients With HR+/HER2− Early Breast Cancer and Oncotype DX Recurrence Score ≥18
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study
ESMO Open 2024 Sep 30;9(10)103733, Á Guerrero-Zotano, JM Pérez-García, M Ruiz-Borrego, B Bermejo, M Gil-Gil, J de la Haba, E Alba Conejo, V Quiroga, V Carañana, A Urruticoechea, S Morales, M Bellet, A Antón, M Fernández-Abad, P Sánchez-Rovira, L Calabuig, J Pérez-Escuredo, M Sampayo-Cordero, J Cortés, A Llombart-CussacFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.